Navigation Links
FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System
Date:5/11/2010

BETHLEHEM, Pa., May 11 /PRNewswire/ -- The U.S. Food and Drug Administration recently approved an application that permits B. Braun Medical Inc. (B. Braun) to deliver FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX® Drug Delivery System.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

Used in hospitals and healthcare centers to treat a wide variety of bacterial infections, Cefepime should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in the treatment of pneumonia, uncomplicated and complicated urinary tract infections, empiric therapy for febrile neutropenic patients, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. The availability of 1g and 2g Cefepime in the DUPLEX® System will mean faster, safer and accurate administration of Cefepime to patients as it can be stored ready-to-use in a container wherever and whenever it is needed.

"Making 1g and 2g Cefepime available to healthcare workers in B. Braun's DUPLEX® Drug Delivery System gives them another weapon to combat challenging infections with speed, safety and accuracy," said Rob Albert, Vice President of Marketing for B. Braun Medical Inc.

The DUPLEX® Drug Delivery System is a ready-to-use, two-compartment, flexible, eco-friendly IV container that stores pre-measured pharmaceuticals and diluent doses. DUPLEX® is easy to stock as it can be stored at room temperature, with 18-month minimum dating, and fits in automated medication dispensing systems. Unit dose-based DUPLEX® helps healthcare facilities achieve Joint Commission and USP Chapter < 797 > compliance that improves the practice of healthcare professionals while advancing patient safety.

Healthcare workers administering 1g or 2g Cefepime through DUPLEX® simply fold and squeeze the container and shake it to mix the pharmaceuticals and diluent. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

Customers interested in obtaining more information can call: 1-888-422-7286 (1-888-4BBRAUN).

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals.  For more information, call 800-227-2862, e-mail us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.


'/>"/>
SOURCE B. Braun Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. FDA Approves Natazia(TM), a New Oral Contraceptive for the Prevention of Pregnancy
2. FDA Approves New Combination Product Oral Contraceptive
3. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
4. FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
5. FDA Approves New Device for Adults with Severe and Persistent Asthma
6. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
7. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
8. FDA Approves First Totally Implanted Hearing System
9. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
10. FDA Approves Name Change for Heartburn Drug Kapidex
11. FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):